The Technical AnalystExchange: EURONEXT Industry: Diagnostics & Research
Median Technologies SA Price, Forecast, Insider, Ratings, Fundamentals & Signals
5.92% €3.40
America/New_York / 17 mai 2024 @ 11:35
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 62.45 mill |
| EPS: | -1.250 |
| P/E: | -2.72 |
| Earnings Date: | Apr 25, 2024 |
| SharesOutstanding: | 18.37 mill |
| Avg Daily Volume: | 0.0533 mill |
| RATING 2024-05-17 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/21 | 4/21 | 2/22 | 4/22 | 2/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | n/a | n/a | n/a | n/a | n/a | n/a |
| Asset | n/a | n/a | n/a | n/a | n/a | n/a |
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.72 | sector: PE 17.68 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.33x |
| Company: PE -2.72 | industry: PE 8.23 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
€ 3.09 - 3.72 ( +/- 9.26%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | €3.40 (5.92% ) |
| Volume | 0.0895 mill |
| Avg. Vol. | 0.0533 mill |
| % of Avg. Vol | 167.80 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ALMDT.PA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ALMDT.PA
Median Technologies SA develops and markets software products and platforms for medical image analysis in France, the United States, Canada, the United Kingdom, China, and internationally. The company offers iBiops, an end-to-end AI-powered technology software as a medical device that integrates and optimizes the entire medical imaging workflow; and iSee for image analysis services in clinical trials. It also provides imaging contract research services, such as study start up, image and clinical data management, scientific consulting, independent reviews, image data processing and site support, and study close-out for studies. Median Technologies SA has a research collaboration agreement with the University of California. The company was founded in 2002 and is based in Valbonne, France.